Asunaprevir

Asunaprevir (formerly BMS-650032, brand name in Japan and Russia Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It is undergoing development by Bristol-Myers Squibb and is currently in Phase III clinical trials.
Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3.